Back
ESC Premium Access

Refining dual antithrombotic treatment in patients with chronic coronary syndrome

Session: Latest Science in ACS
Topic: Epidemiology, Prognosis, Outcome
Speaker: Doctor K. Olesen (Aarhus, DK)
Event: ESC Congress 2021 - The Digital Experience

Congress Session

0

About the speaker

Doctor Kevin Kris Warnakula Olesen

Aarhus University Hospital, Aarhus (Denmark)
2 presentations
0 follower

10 more presentations in this session

Colchicine in Acute Myocardial Infarction

Speaker: Professor N. Mewton (Bron, FR)

Access
Slides
Video
0
Thumbnail

Effects of Sacubitril/valsartan compared with ramipril on coronary events after myocardial infarction - Results from the PARADISE-MI Trial

Speaker: Professor R. Mehran (New York, US)

Access
Slides
Video
0
Thumbnail

Cost-effective analysis of HOST-EXAM

Speaker: Doctor H. Kim (Seoul, KR)

Access
Slides
Video
0
Thumbnail

REDUCE-IT PRIOR MI: Reduction in Ischemic Events, Including Cardiovascular Mortality, with Icosapent Ethyl in Patients with Prior Myocardial Infarction

Speaker: Professor D. Bhatt (Boston, US)

Access
Slides
Video
0
Thumbnail

BIC-8 Revisited - Copeptin together with high sensitivity troponin for managemnent of suspected NSTE-ACS

Speaker: Assistant Professor E. Giannitsis (Heidelberg, DE)

Access
Slides
Video
0
Thumbnail

Access the full session

Latest Science in ACS

Speakers: Doctor K. Olesen, Professor N. Mewton, Professor R. Mehran, Doctor H. Kim, Professor D. Bhatt...
Access
0
Thumbnail

About the event

Image

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Congress
logo Image

Related content

ESC Premium Access

Predictors of adverse clinical outcomes in atrial fibrillation patients with concomitant renal impairment under rivaroxaban therapy

27 August 2021

ESC Premium Access

Age-adjusted risk factors are independently associated with an increased risk of ischaemic stroke, transient ischaemic stroke and systemic embolism in the ETNA-AF-Europe registry

27 August 2021

ESC Premium Access

RACE V: predictors of atrial fibrillation progression

27 August 2021

This platform is supported by

logo Novo Nordisk